Paul Yeung, MD, MPH, a former resident in the Yale Department of Psychiatry and former chief fellow at the Yale Child Study Center, served as the clinical leader for the development of a novel treatment for migraine headaches.
Fremanezumab is a monoclonal antibody that binds the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the CGRP receptor. This innovative approach to treating migraine headaches was approved by the U.S. Food and Drug Administration on Sept. 14.
Yeung oversaw the pivotal clinical studies that were published in the New England Journal of Medicine and in the Journal of the American Medical Association.
Yeung practices psychiatry in Pennsylvania.
Submitted by Christopher Gardner on September 19, 2018